1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY |
|||||||||||
|
UNI - EN REPORT No |
107 | / |
2026 |
|
||||||
Date of issue: |
2026-03-20 |
||||||||||
Short name of the issuer |
|||||||||||
SOPHARMA AD |
|||||||||||
Subject |
|||||||||||
Notification for sales revenues for February 2026 |
|||||||||||
Official market - legal basis |
|||||||||||
Art. 56. 1. 2 of Act on Public Offering |
|||||||||||
Unofficial market - legal basis |
|||||||||||
Contents of the report: |
|||||||||||
Sofia, Bulgaria, March 20, 2026 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that February 2026 the Company recorded an increase in sales of 106% compared to the same month of the previous year, incl. 8% increase in domestic sales and 230% increase in export sales. For the period from the beginning of 2026, the Company achieved sales growth of 6%, including a 36% decrease in domestic sales and a 37% growth in export sales. |
|||||||||||
Annexes |
|||||||||||
File |
Description |
||||||||||
Notification for sales revenues for February 2026 |
|||||||||||
SOPHARMA AD |
|||||||||||||
(fullname of the issuer) |
|||||||||||||
SOPHARMA AD |
Farmaceutyczny (far) |
||||||||||||
(short name of the issuer) |
(sector according to clasification of the WSE in Warsow) |
||||||||||||
1220 |
Sofia |
||||||||||||
(post code) |
(city) |
||||||||||||
IlienskoShosse |
16 | ||||||||||||
(street) |
(number) |
||||||||||||
+359 2 813 42 00 |
+359 2 936 02 86 |
||||||||||||
(phone number) |
(fax) |
||||||||||||
(e-mail) |
(web site) |
||||||||||||
nd |
|||||||||||||
(NIP) |
(REGON) |
||||||||||||
SIGNATURE OF PERSONS REPRESENTING THE COMPANY |
|||||
Date |
Name |
Position / Function |
Signature |
||
2026-03-20 |
Ognian Ivanov Donev |
Executive Director |
|||
